Skip to main content
SpringerLink
Log in

Urologika

  • Chapter
Arzneiverordnungs-Report 2009

  • 924 Accesses

Zusammenfassung

Urologika werden zur Behandlung von Miktionsstörungen im weitesten Sinne angewandt, denen Erkrankungen der Prostata und der Blase sowie verschiedene andere urologische Störungen zugrunde liegen können. Nach einzelnen Indikationen differenziert, wurden vor allem Alpha1-Rezeptorenblocker und urologische Spasmolytika verordnet (Abbildung 43.1).

Verordnungen von Urologika 1999 bis 2008. Gesamtverordnungen nach definierten Tagesdosen

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abrams P, Freeman R, Anderström C, Mattiasson A (1998): Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81: 801–810.

    CAS  PubMed  Google Scholar 

  • Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003193.

    PubMed  Google Scholar 

  • Blake-James BT, Rashidian A, Ikeda Y, Emberton M (2007): The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99: 85–96.

    Article  CAS  PubMed  Google Scholar 

  • Boyle P, Gould AL, Roehrborn CG (1996): Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48: 398–405.

    Article  CAS  PubMed  Google Scholar 

  • Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ et al (1998): Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA 280: 1995–2000.

    Article  CAS  PubMed  Google Scholar 

  • Chapple CR (1996): Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 29: 129–144.

    CAS  PubMed  Google Scholar 

  • Chapple CR (2000): Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 (5A Suppl.): 33–46.

    Article  CAS  PubMed  Google Scholar 

  • Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group (2004): Randomized, double-blind placeboand tolterodinecontrolled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Brit J Urol Int. 93: 303–310.

    CAS  Google Scholar 

  • Djavan B, Marberger M (1999). A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1–13.

    Article  CAS  PubMed  Google Scholar 

  • Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S (1999): Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 10: 283–289.

    Article  CAS  Google Scholar 

  • European Medicines Agency (EMEA) (2004): Ausschuss für Humanarzneimittel. Europäischer Bewertungsbericht (EPAR) Emselex. Im Internet: http://www.emea.eu.int/humandocs/HUMANS/EPAR/emselex/emselex.htm

    Google Scholar 

  • Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC (1998): 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 160: 12–16.

    Article  CAS  PubMed  Google Scholar 

  • Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G (1995): Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 288: 201–207.

    Article  CAS  PubMed  Google Scholar 

  • Haab F, Stewart L, Dwyer P (2004): Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45: 420–429.

    Article  CAS  PubMed  Google Scholar 

  • Harvey M-A, Baker K, Wells GA (2003): Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis. Am J Obstet Gynecol 185: 56–61.

    Article  Google Scholar 

  • Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2005; 3: CD005429

    PubMed  Google Scholar 

  • Iselin CE, Schmidlin F, Borst F, Rohner S, Graber P (1997): Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate. Brit J Urol 79: 915–919.

    CAS  PubMed  Google Scholar 

  • Janssen CCM, Lagro-Janssen ALM, Felling AJA (2003): The effects of physiotherapy for female urinary incontinence: individual compared with group treatment. Brit J Urol Int 87: 201–206.

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2008): Rahmenvorgaben nach § 84 Absatz 7 SGB V — Arzneimittel — und Hinweise zur Vereinbarung nach § 84 Absatz 7 a SGB V für das Jahr 2008 vom 17. September 2007. Dtsch Ärztebl 105: A 595–A 596.

    Google Scholar 

  • Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM (2005): Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 95: 81–85.

    Article  PubMed  Google Scholar 

  • Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB and the Prospective European Doxazosin and Combination Therapy Study Investigators (2003): Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PRE-DICT) trial. Urology 61: 119–126.

    Article  PubMed  Google Scholar 

  • McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM et al for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003): The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398.

    Article  CAS  PubMed  Google Scholar 

  • McDowell BJ, Engberg S, Sereika S, Donovan N, Jubeck ME, Weber E, Engberg R (1999): Effectiveness of behavioral therapy to treat incontinence in homebound older adults. J Am Geriatr Soc 47: 309–318.

    CAS  PubMed  Google Scholar 

  • Milani S, Djavan B (2005): Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 95(Suppl 4):29–36.

    Article  CAS  PubMed  Google Scholar 

  • Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group. Duloxetine vs placebo in the treatment of stress urinary incontinence: a fourcontinent randomized clinical trial. Brit J Urol Int. 2004; 93: 311–318.

    CAS  Google Scholar 

  • Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M (1990): Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Brit J Urol 66: 479–485.

    Article  CAS  PubMed  Google Scholar 

  • Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003781.

    PubMed  Google Scholar 

  • Ouslander JG, Blaustein J, Connor A, Pitt A (1988): Habit training and oxybutynin for incontinence in nursing home patients: a placebo-controlled trial. J Am Geriatr Soc 36: 40–46.

    CAS  PubMed  Google Scholar 

  • Ouslander JG, Schnelle JF, Uman G, Fingold S, Nigam JG et al (1995): Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 43: 610–617.

    CAS  PubMed  Google Scholar 

  • Riva D, Casolati E (1984): Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obst Gyn 11: 37–42.

    CAS  Google Scholar 

  • Stöhrer M, Bauer P, Giannetti BM, Richter R, Burgdörfer H, Mürtz G (1991): Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urol Int 47: 138–143.

    Article  PubMed  Google Scholar 

  • Subak LL, Quesenberry CP, Posner SF, Cattolica E, Soghikian K (2003): The effect of behavioral therapy on urinary incontinence: a randomized controlled trial. Obstet Gynecol 100: 72–78.

    Article  Google Scholar 

  • Szonyi G, Collas DM, Ding YY, Malone-Lee JG (1995): Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 24: 287–291.

    Article  CAS  PubMed  Google Scholar 

  • Tapp AJS, Cardozo LD, Versi E, Cooper D (1990): The treatment of detrusor instability in postmenopausal women with oxyxbutynin chloride: a double blind placebo controlled study. Brit J Obstet Gynaec 97: 521–526.

    CAS  PubMed  Google Scholar 

  • Thüroff JW, Bunke B, Ebner A, Faber P, de Geeter P et al (1991): Randomized, doubleblind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145: 813–817.

    PubMed  Google Scholar 

  • Thüroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U et al (1998): Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16 (suppl): S48–S61.

    Article  PubMed  Google Scholar 

  • Tsujii T (2000): Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int J Urol 7: 199–205.

    Article  CAS  PubMed  Google Scholar 

  • Wehnert J, Sage S (1992): Therapie der Blaseninstabilität und Urge-Inkontinenz mit Propiverin hydrochlorid (Mictonorm®) und Oxybutyninchlorid (Dridase®) — eine randomisierte Cross-over-Vergleichsstudie. Akt Urol 23: 7–11.

    Article  Google Scholar 

  • Wilt TJ, Mac Donald R, Rutks I (2003): Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003;(1):CD002081.

    Google Scholar 

  • Wyman JF, Fantl JA, McClish DK, Bump RC (1998): Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol 179: 999–1007.

    Article  CAS  PubMed  Google Scholar 

  • Zorzitto ML, Holliday PJ, Jewett MAS, Herschorn S, Fernie GR (1989): Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 18: 195–200.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Pharmakologie, Zentralkrankenhaus Sankt-Jürgen-Straße, 28205, Bremen

    Prof. Dr. med. Bernd Mühlbauer

  2. Pharmakologisches Institut der Universität, Wilhelmstraße 56, 72074, Tübingen

    Prof. Dr. med. Hartmut Osswald

Authors
  1. Prof. Dr. med. Bernd Mühlbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Hartmut Osswald
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein, Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Mühlbauer, B., Osswald, H. (2009). Urologika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2009. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01080-4_43

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01080-4_43

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01079-8

  • Online ISBN: 978-3-642-01080-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation